Efficiency of day 4 compared to day 6 stem cell mobilization in allogeneic stem cell donors

Published:January 09, 2020DOI:



      Granulocyte colony stimulating factor (G-CSF) given for 4–6 days is commonly used for mobilization of allogeneic stem cell donors. The primary objective of this study is to compare the yield of stem cell mobilization, assessed using a surrogate endpoint of CD34+ cell count, between Day 4 and Day 6.

      Study design and Methods

      In this retrospective study we included all allogeneic stem cell donors mobilized with G-CSF for 6 days from January 2003 until October 2015 in the bone marrow transplantation unit at a tertiary academic center. Of 106 donor records reviewed, 84 were with available data and selected for the study.


      We included 84 donors with median age and weight of 19 years and 60 kg respectively. The median Day 4 WBC and CD34+ cell count were 37.4 × 109/L and 54 × 106/L respectively; while the median Day 6 WBC and CD34+ cell count were 44.4 × 109/L and 86 × 106/L respectively with a statistically significant difference from Day 4 (P < 0.001). In the multivariable model, there were no significant impact of donor’s age (P = 0.215), weight (P = 0.108), height (P = 0.428) and mean corpuscular volume (P = 0.263) on the difference in CD34+ cell yield. However, the donor's blood group AB predicated a significantly higher difference (P = 0.036).


      Six days of G-CSF mobilization achieves higher CD34+ cell count than 4 days in allogeneic stem cell donors especially in donors with blood group AB, albeit both approaches give count higher than the successful collection threshold.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Transfusion and Apheresis Science
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Wang T.-F.
        • Wen S.-H.
        • Chen R.-L.
        • Lu C.-J.
        • Zheng Y.-J.
        • Yang S.-H.
        • et al.
        Factors Associated with Peripheral Blood Stem Cell Yield in Volunteer Donors Mobilized with Granulocyte Colony-Stimulating Factors: The Impact of Donor Characteristics and Procedural Settings.
        Biol. Blood Marrow Transplant. 2008; 14: 1305-13011
        • de la Rubia J.
        • Arbona C.
        • de Arriba F.
        • del Canizo C.
        • Brunet S.
        • Zamora C.
        • et al.
        Analysis of factors associated with low peripheral blood progenitor cell collection in normal donors.
        Transfusion. 2002; 42: 4-9
        • Holig K.
        G-CSF in healthy allogeneic stem cell donors.
        Transfus. Med. Hemother. 2013; 40: 225-235
        • Hauge A.W.
        • Haastrup E.K.
        • Sengelov H.
        • Minulescu L.
        • Dickmeiss E.
        • Fischer-Nielsen A.
        Addition of plerixafor for CD34+ cell mobilization in six healthy stem cell donors ensured satisfactory grafts for transplantation.
        Transfusion. 2014; 54: 1055-1058
        • Gattillo S.
        • Marktel S.
        • Rizzo L.
        • Malato S.
        • Malabarba L.
        • Coppola M.
        • et al.
        Plerixafor on demand in ten healthy family donors as a rescue strategy to achieve an adequate graft for stem cell transplantation.
        Transfusion. 2015; 55: 1993-2000
        • Stroncek D.F.
        • Clay M.E.
        • Petzoldt M.L.
        • Smith J.
        • Jaszcz W.
        • Oldham F.B.
        • et al.
        Treatment of normal individuals with granulocyte-colony-stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells.
        Transfusion. 1996; 36: 601-610
        • Grigg A.P.
        • Roberts A.W.
        • Raunow H.
        • Houghton S.
        • Layton J.E.
        • Boyd A.W.
        • et al.
        Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers.
        Blood. 1995; 86: 4437-4445
        • Tomblyn M.
        • Gordon L.I.
        • Singhal S.
        • Tallman M.S.
        • Williams S.
        • Winter J.N.
        • et al.
        Use of total leukocyte and platelet counts to guide stem cell apheresis in healthy allogeneic donors treated with G-CSF.
        Bone Marrow Transplant. 2005; 36: 663-666
        • Anderlini P.
        • Przepiorka D.
        • Seong C.
        • Smith T.L.
        • Huh Y.O.
        • Lauppe J.
        • et al.
        Factors affecting mobilization of CD34+ cells in normal donors treated with filgrastim.
        Transfusion. 1997; 37: 507-512
        • Sutherland D.R.
        • Anderson L.
        • Keeney M.
        • Nayar R.
        • Chin-Yee I.
        The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering.
        J. Hematother. 1996; 5: 213-226
        • Weaver C.H.
        • Hazelton B.
        • Birch R.
        • Palmer P.
        • Allen C.
        • Schwartzberg L.
        • et al.
        An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy.
        Blood. 1995; 86: 3961-3969
        • Lysák D.
        • Koza V.
        • Jindra P.
        Factors affecting PBSC mobilization and collection in healthy donors.
        Transfus. Apher. Sci. 2005; 33: 275-283
        • Cohen M.
        • Hurtado-Ziola N.
        • Varki A.
        ABO blood group glycans modulate sialic acid recognition on erythrocytes.
        Blood. 2009; 114: 3668-3676
        • Daniels G.
        • Green C.
        Expression of red cell surface antigens during erythropoiesis.
        Vox Sang. 2000; 78: 149-153
        • Norol F.
        • Bonin P.
        • Charpentier F.
        • Bierling P.
        • Beaujean F.
        • Cartron J.P.
        • et al.
        Apparent reactivation of a red cell alloantibody in a healthy individual after G-CSF administration.
        Br J Haematol. 1998; 103: 256-258